

Tobias Walbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7500449/publications.pdf>

Version: 2024-02-01

56
papers

2,077
citations

279798

23
h-index

243625

44
g-index

56
all docs

56
docs citations

56
times ranked

2884
citing authors

#	ARTICLE	IF	CITATIONS
1	Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial. <i>Neuro-Oncology</i> , 2023, 25, 146-156.	1.2	23
2	OUP accepted manuscript. <i>Neuro-Oncology</i> , 2022, , .	1.2	0
3	Neuro-oncology and supportive care: the role of the neurologist. <i>Neurological Sciences</i> , 2022, 43, 939-950.	1.9	5
4	Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. <i>Neuro-Oncology</i> , 2022, 24, 1126-1139.	1.2	9
5	Health-related quality of life in meningioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab089.	0.7	11
6	DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features. <i>Neuro-Oncology</i> , 2021, 23, 1292-1303.	1.2	6
7	A serum-based DNA methylation assay provides accurate detection of glioma. <i>Neuro-Oncology</i> , 2021, 23, 1494-1508.	1.2	53
8	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.6	9
9	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021, 23, 1835-1844.	1.2	64
10	Caregiver perceptions of end-of-life care in patients with high-grade glioma. <i>Neuro-Oncology Practice</i> , 2021, 8, 171-178.	1.6	7
11	Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Brain Cancer. <i>Journal of Palliative Medicine</i> , 2020, 23, 415-421.	1.1	6
12	Effect of seizure timing on long-term survival in patients with brain tumor. <i>Epilepsy and Behavior</i> , 2020, 111, 107307.	1.7	7
13	The economic impact of glioma survivorship. <i>Neurology</i> , 2020, 95, e1575-e1581.	1.1	18
14	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. <i>JAMA Oncology</i> , 2020, 6, 1939.	7.1	84
15	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.6	19
16	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1505-1515.	1.2	27
17	Rapid multicontrast brain imaging on a 0.35T MRâ€œlinac. <i>Medical Physics</i> , 2020, 47, 4064-4076.	3.0	21
18	Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 353-361.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
20	Health-Related Quality of Life Related to Toxicity Treatments in Central Nervous System Metastases. , 2020, , 373-382.		1
21	Impaired neurocognitive function in glioma patients: from pathophysiology to novel intervention strategies. <i>Current Opinion in Neurology</i> , 2020, 33, 716-722.	3.6	5
22	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
23	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
24	Clinical and research applications of a brain tumor tissue bank in the age of precision medicine. <i>Personalized Medicine</i> , 2019, 16, 145-156.	1.5	4
25	Simultaneous care in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 302-303.	1.2	2
26	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	10.7	32
27	Brain metastasis: clinical manifestations, symptom management, and palliative care. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 75-88.	1.8	45
28	Maintaining quality of life near the end of life: hospice in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 439-440.	1.2	5
29	The safety of magnetic resonance imaging-guided laser interstitial thermal therapy for cerebral radiation necrosis. <i>Journal of Neuro-Oncology</i> , 2018, 138, 609-617.	2.9	32
30	Cerebral edema induced by laser interstitial thermal therapy and radiotherapy in close succession in patients with brain tumor. <i>Lasers in Surgery and Medicine</i> , 2018, 50, 917-923.	2.1	21
31	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.2	135
32	The role of tumor board conferences in neuro-oncology: a nationwide provider survey. <i>Journal of Neuro-Oncology</i> , 2017, 133, 1-7.	2.9	43
33	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.	1.2	39
34	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
35	Recent Advances in the Classification and Treatment of Ependymomas. <i>Current Treatment Options in Oncology</i> , 2017, 18, 55.	3.0	20
36	Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 1709-1726.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
38	Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey. <i>Journal of Neuro-Oncology</i> , 2016, 126, 337-345.	2.9	41
39	End-of-life care in patients with primary malignant brain tumors: early is better. <i>Neuro-Oncology</i> , 2016, 18, 7-8.	1.2	22
40	International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2015, 2, 62-69.	1.6	18
41	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. <i>Journal of Neuro-Oncology</i> , 2015, 121, 341-348.	2.9	11
42	Palliative and Supportive Care for Glioma Patients. <i>Cancer Treatment and Research</i> , 2015, 163, 171-184.	0.5	41
43	Through the patient's eyes: the value of a comprehensive brain tumor center. <i>Journal of Neuro-Oncology</i> , 2014, 119, 465-472.	2.9	12
44	Integration of palliative care into the neuro-oncology practice: patterns in the United States. <i>Neuro-Oncology Practice</i> , 2014, 1, 3-7.	1.6	40
45	End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. <i>Journal of Neuro-Oncology</i> , 2014, 117, 217-224.	2.9	93
46	Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 449-451.	7.7	50
47	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 273-280.	2.9	26
48	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 509-518.	2.8	20
49	Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. <i>Future Oncology</i> , 2010, 6, 287-297.	2.4	20
50	Symptomatic Neurocutaneous Melanosis and Dandy-Walker Malformation in an Adult. <i>Journal of Clinical Oncology</i> , 2009, 27, 2886-2887.	1.6	20
51	The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. <i>International Journal of Clinical Oncology</i> , 2009, 14, 299-306.	2.2	56
52	The Impact of Accreditation Council for Graduate Medical Education Duty Hours, the July Phenomenon, and Hospital Teaching Status on Stroke Outcomes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 232-238.	1.6	33
53	Impact of ACGME Standards Is Yet To Be Determined. <i>American Journal of Medicine</i> , 2008, 121, e21-e22.	1.5	2
54	Health-related quality of life in patients with narcolepsy. <i>Sleep Medicine</i> , 2007, 8, 733-741.	1.6	134

#	ARTICLE	IF	CITATIONS
55	The Socioeconomic Impact of Narcolepsy. <i>Sleep</i> , 2004, 27, 1123-1128.	1.1	77
56	Systematic Assessment of Decision Models in Parkinson's Disease. <i>Value in Health</i> , 2004, 7, 610-626.	0.3	23